Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:vaccine_platform
|
| gptkbp:administeredBy |
intramuscular injection
|
| gptkbp:advantage |
induces strong immune response
low pre-existing immunity in humans |
| gptkbp:basedOn |
chimpanzee adenovirus vector
|
| gptkbp:developedBy |
gptkb:University_of_Oxford
|
| gptkbp:enables |
delivery of genetic material encoding antigens
|
| gptkbp:introducedIn |
2012
|
| gptkbp:relatedTo |
gptkb:Oxford_Vaccine_Group
gptkb:AstraZeneca_COVID-19_vaccine |
| gptkbp:targetedDiseases |
gptkb:COVID-19
gptkb:Zika_virus gptkb:influenza gptkb:MERS |
| gptkbp:usedFor |
vaccine development
|
| gptkbp:usedIn |
gptkb:ChAdOx1_nCoV-19
gptkb:Oxford–AstraZeneca_COVID-19_vaccine ChAdOx1 MERS vaccine |
| gptkbp:vectorFor |
non-replicating viral vector
|
| gptkbp:bfsParent |
gptkb:chimpanzee_adenovirus
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
ChAdOx1 vaccine platform
|